PLSE
PULSE BIOSCIENCES, INC.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$53.87
+6.44%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$50.59
From 52W high−2.41%
Volume832455.00
Market cap$3.84B
P/E (TTM)—
P/S (TTM)3242.3x
Div yield—
Key dataSep 18, 2026
Open
$50.59
From 52W high
−2.41%
Volume
832455.00
Market cap
$3.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−46.9x
P/E (TTM)
—
RSI (14)
56.4
MomentumView details →
1D Return
+6.44%
YTD Return
+277.64%
SummaryUpdated Jun 1, 2026
Pulse Biosciences, Inc. (NASDAQ:PLSE) is a bioelectric medicine company founded in 2014 and headquartered in Hayward, California. Originally incorporated as Electroblate, Inc., the company changed its name to Pulse Biosciences in December 2015 and went public in May 2016. The company has undergone significant strategic evolution, initially focusing on dermatological applications before pivoting to cardiac and soft tissue ablation markets. Pulse Biosciences is currently in the clinical development stage, advancing multiple medical devices based on its proprietary nanosecond Pulsed Field Ablation (nsPFA) technology across three primary therapeutic areas.
Similar companies
Latest newsMore news →
Pulse Biosciences terminated its at-the-market offering program under its prior equity distribution agreement with TD Securities (USA) LLC dated February 19, 2026.5d agoPulse Biosciences entered into an equity distribution agreement with Mizuho Securities USA LLC as sales agent for an at-the-market offering of up to $85 million of common stock.5d agoPulse Biosciences, Inc reported a second-quarter loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and wider than the year-ago loss of $0.28 per share.45d ago